Brokerages Set Cabot Corporation (NYSE:CBT) Price Target at $73.75

Cabot Corporation (NYSE:CBT) has earned an average rating of “Hold” from the six brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $76.25.

Several equities research analysts have issued reports on CBT shares. Mizuho lifted their target price on shares of Cabot from $75.00 to $80.00 and gave the stock a “neutral” rating in a research note on Wednesday. Jefferies Financial Group reaffirmed a “buy” rating and set a $85.00 target price on shares of Cabot in a research note on Wednesday, February 4th. Zacks Research raised shares of Cabot from a “strong sell” rating to a “hold” rating in a research note on Tuesday, January 27th. Wall Street Zen raised shares of Cabot from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, UBS Group boosted their price target on shares of Cabot from $81.00 to $86.00 and gave the company a “neutral” rating in a research report on Friday.

Cabot Trading Up 5.4%

Shares of CBT opened at $85.71 on Tuesday. Cabot has a 52-week low of $58.33 and a 52-week high of $86.04. The company has a quick ratio of 1.09, a current ratio of 1.45 and a debt-to-equity ratio of 0.51. The firm’s fifty day moving average is $73.94 and its two-hundred day moving average is $70.43. The stock has a market cap of $4.42 billion, a PE ratio of 16.20, a price-to-earnings-growth ratio of 11.33 and a beta of 0.78.

Cabot (NYSE:CBT) last announced its earnings results on Tuesday, May 5th. The specialty chemicals company reported $1.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.14. Cabot had a net margin of 7.97% and a return on equity of 21.33%. The company had revenue of $904.00 million for the quarter, compared to analysts’ expectations of $900.31 million. During the same quarter in the previous year, the company posted $1.90 EPS. The firm’s quarterly revenue was down 3.4% on a year-over-year basis. Cabot has set its FY 2026 guidance at 6.000-6.50 EPS. Research analysts forecast that Cabot will post 6.25 earnings per share for the current fiscal year.

Cabot Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 29th will be given a dividend of $0.4725 per share. The ex-dividend date is Friday, May 29th. This is an increase from Cabot’s previous quarterly dividend of $0.45. This represents a $1.89 annualized dividend and a yield of 2.2%. Cabot’s dividend payout ratio (DPR) is 34.03%.

Institutional Investors Weigh In On Cabot

Several hedge funds and other institutional investors have recently bought and sold shares of CBT. NewEdge Advisors LLC increased its position in Cabot by 2,559.5% during the first quarter. NewEdge Advisors LLC now owns 984 shares of the specialty chemicals company’s stock worth $82,000 after purchasing an additional 947 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Cabot by 32.5% during the first quarter. Goldman Sachs Group Inc. now owns 442,646 shares of the specialty chemicals company’s stock worth $36,802,000 after purchasing an additional 108,645 shares during the last quarter. Empowered Funds LLC increased its position in Cabot by 102.6% during the first quarter. Empowered Funds LLC now owns 28,162 shares of the specialty chemicals company’s stock worth $2,341,000 after purchasing an additional 14,260 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Cabot by 3.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 122,022 shares of the specialty chemicals company’s stock worth $10,145,000 after purchasing an additional 4,048 shares during the last quarter. Finally, Geneos Wealth Management Inc. increased its position in Cabot by 409.0% during the first quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock worth $38,000 after purchasing an additional 364 shares during the last quarter. 93.18% of the stock is currently owned by institutional investors and hedge funds.

Cabot Company Profile

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.